ALKS 7290 was generally well tolerated at all doses in the study, which enrolled 88 healthy volunteers and 50 adults.

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and ...

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

Alkermes ( ) just unveiled an announcement. On Sept. 21, 2026, Alkermes reported positive topline results from a phase 1 proof-of-concept study of ALKS 7290, an oral orexin 2 rece ...

The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD ...

Shares of Alkermes ( ALKS ), a global biopharmaceutical company focused on neuroscience, tumbled just over 7% on Friday, ...

Novo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than ...

Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of ...

Following this transaction, the executive continues to hold approximately 102,000 shares directly, representing an insider ownership stake of 0.06%. What was the market valuation of the security at ...

DUBLIN--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) ...

Learn more Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's confidence in ALKS7290 and reinforced the potential of its broader "orexin pipeline," RBC ...

Avadel Pharmaceuticals (AVDL) stock jumped Wednesday, and Alkermes (ALKS) shares recovered somewhat from a steep dive, after the latter agreed to buy the former for up to $2.1 billion. Evercore ISI ...